To compare the effects of cilazapril, carvedilol and their combination in preventing left ventricular remodelling (LVRM) after acute myocardial infarction (AMI) in rats.
Introduction
Left ventricular remodelling (LVRM) after myocardial infarction (MI) plays a very important role in developing left ventricular (LV) dysfunction and congestive heart failure (CHF), and is characterised by infarct expansion, hypertrophy of the non-infarcted myocardium, and alteration of LV geometry. Studies [1] [2] [3] [4] have demonstrated that angiotensin-converting enzyme inhibitors (ACE-I), including cilazapril, are effective in preventing LVRM when used appropriately after acute MI (AMI). Carvedilol, the third-generation β-blocker, is a unique, multiple-action drug with non-selective β-blockade, α 1 -blockade and antioxidant effects. Clinical studies 5, 6 have shown that carvedilol can attenuate LVRM in patients with ischaemic heart failure and prevent LVRM in patients with AMI. Therefore, on the basis of the beneficial effects of carvedilol and cilazapril on LVRM, we hypothesised that the effects of their combination would be superior to those with each drug alone. Thus, the purpose of this study was to compare the beneficial effects of cilazapril and carvedilol, alone and in combination, on LVRM after AMI in rats.
Materials and methods
Experimental rats and groups AMI was induced in 133 female Sprague-Dawley (SD) rats (body weight: 200-250 g) as described below. Twenty-four hours after the operation, the 100 surviving rats were randomised to the following groups: (1) AMI controls (n=25); (2) cilazapril (n=25; 1 mg/kg/day); (3) carvedilol (n=25; 1 mg/kg/day), and (4) cilazapril+carvedilol (combination) (n=25; both 1 mg/kg/day) groups.
Sham-operated rats (n=17) were randomly selected to act as AMI controls.
Methods
AMI in rats was induced using the method previously reported by Olivetti 7 by ligating the left coronary artery, using a 6-0 proline suture. In the sham-operated rats, a suture was tied loosely around the left coronary artery without ligation.
Twenty-four hours after AMI, cilazapril and carvedilol (both donated by Roche Pharmaceutical Company) were given by direct gastric gavage in solutions of 25 mg% and 12.5 mg%, respectively; cilazapril, was given once-daily and carvedilol twice-daily.When the solution was delivered in the same volume of 8 mg/kg/day, (i.e. 2 ml per 250 g body weight) it approximated the target doses of cilazapril, carvedilol and the combination groups, respectively. The rats in the control groups were given the same volume of drinking water at the same time.
Haemodynamic measurements
Four weeks after the initiation of therapy, haemodynamic studies were performed in each group using the methods described by Pfeffer. 8 First, the rat was weighed and anaesthetised, then, the right carotid artery was separated and cannulated with a 20G sheathed needle. After extracting the needle, the end of the sheath was connected to the energy exchanger of an eight-channel physiological recorder, via a heparinised plastic tube. After equilibrating with the air pressure, the ascending aortic systolic pressure (SBP), diastolic pressure (DBP) and mean pressure (MBP) were recorded. Subsequently, the sheath was retrograded into left ventricle (LV), and the LV systolic pressure (LVSP), end diastolic pressure (LVEDP), and LV pressure maximal rate of rise and fall (±dp/dt) were recorded. The heart rate was also recorded synchronally.
Pathological analysis
After haemodynamic studies, the heart was arrested in diastole, using an intravenous injection of 2-3 ml 10% KCL via the femoral vein.The thorax was rapidly opened and the aortic arch was ligated with the head of the sheath fixed in the ascending aorta. The end of the sheath was connected to an irrigating bottle containing 10% formalin. The coronary arteries were then perfused with the fixative and the right atrium was opened to allow the drainage of blood and fixative. The procedure lasted for 20-30 minutes and the heart was fixed. Subsequently, the heart was excised and preserved in 10% formalin after the atria and great vessels had been trimmed away.
Heart weight: The two ventricles were separated by incising the RV along the septum and weighed using an electronic balance. The weights of the LV and RV (LVAW and RVAW) were corrected for the body weight, and their relative weights calculated (LVRW and RVRW).
Left ventricular volume (LVV) and length of longitudinal axis (L): These were measured directly, with a cutaneous syringe and vernier calliper, respectively. The mean value of three measurements was recorded as the experimental data from one heart sample.The coefficient of variability of three measurements by one examiner for LVV was 1% (0.95±0.85%); intra-observer variability was 2.1% (2.06±2.10%); and inter-observer variability 2.7% (2.68±1.29%).
LV transverse diameter (D) and infarction size: The LV was cut mid-ventricularly into two parts perpendicular to the longitudinal axis. The apex half was imbedded in paraffin and a 10 µm transverse section was cut from its bottom and mounted on a plastic slice, which was processed by BHEC microscope-computer colour imaging processor. The septal thickness (STh), and maximum and minimal LV transverse diameters (D max and D min ) were then measured and their geometric mean value was calculated according to the following formula: 7 The epicardial and endocardial circumferences, as well as the infarcted circumference, were also measured, and MI size was calculated according to the following formula: 9
Statistical analysis
All variables are expressed as mean±SD. Differences between groups were assessed by ANOVA with a Scheffe's test, and the differences between two groups were assessed by q-test. A value of p<0.05 in a two-tailed distribution was considered statistically significant.
Results
Excluding rats who died or had MI size <35% or >55%, complete data were obtained in 64 rats, comprising AMI control (n=13), cilazapril (n=12), carvedilol (n=12), the combination (n=14), and sham (n=13) groups. There were no significant differences in MI size between the four AMI groups (p>0.05), ( Table 1) .
The effects of cilazapril, carvedilol and their combination on haemodynamics
In the AMI rats, LVEDP was significantly increased (p<0.001) and SBP, DBP, MBP and LVSP were significantly decreased (p<0.05-0.01), as compared with the sham-operated group.
In comparison with the AMI control group, HR were significantly decreased in the carvedilol and the combination group (p<0.05). LVEDP, but not blood pressure and LVSP, were significantly decreased in all therapy groups (all p<0.001), with significantly lower values in the combination group than in the two monotherapy groups (all p<0.05).
The effects of cilazapril, carvedilol and their combination on LVRM and LV function
In the AMI rats, the LVV, LVAW, LVRW, STh and RVAW, RVRW were all significantly increased (all p<0.001), and ±dp/dt and ±dp/dt/LVSP were all significantly decreased (all p<0.001), as compared with the sham-operated group.
In comparison with the AMI control group, LVV, LVAW, LVRW, STh and RVAW, RVRW were all significantly decreased, while ±dp/dt and ±dp/dt/LVSP were all significantly increased in all the treatment groups (p<0.05-0.001), with STh decreased more in the combination group than in the two monothera- py groups (both p<0.05), and ±dp/dt/LVSP increased more in the combination group than in the cilazapril group (p<0.05). (Table 2 ).
Discussion
It is well known that the sympathetic nervous system (SNS) and the renin-angiotensin system (RAS) are activated after AMI, and play key roles in initiating and sustaining LVRM. 10 Experimental and clinical studies [1] [2] [3] [4] have demonstrated that ACE-I are effective in the prevention of post-infarction LVRM, and clinical studies have also shown that carvedilol has beneficial effects in attenuating LVRM in ischaemic heart failure. Theoretically, carvedilol should also be effective in attenuating LVRM after AMI, and its combination with ACE-I should be more effective in this regard than monotherapy. Therefore, in this study we compared the effects of cilazapril and carvedilol, alone and in combination, on LVRM after AMI in rats, and the results are discussed below.
The effects of cilazapril, carvedilol and their combination on haemodynamics
The present study showed that LVEDP was significantly increased after AMI, which was consistent with the reports of Pfeffer 8 and Litwin, 9 and that the elevation in LVEDP was markedly attenuated by treatment with cilazapril, carvedilol and their combination by 44%, 38% and 56%, respectively, with the combination therapy superior to either monotherapy. The beneficial effects of cilazapril on haemodynamic improvement are attributed to the sustained reduction of pre-load and afterload associated with inhibition of the RAS. 3, 4 The mechanisms for the improved haemodynamics by carvedilol have not been elucidated, but may be associated with the pre-vention of excessive sympathetic activation after AMI. 11, 12 The underlying mechanisms for the better effects of combination therapy on haemodynamics probably result from the more complete blockade of both RAS and SNS activation that occurs after AMI.
The effects of cilazapril, carvedilol and their combination on LVRM
LVRM is characterised by infarct expansion and hypertrophy of the non-infarcted myocardium,and is manifested by LV dilatation and dysfunction. 13 The results of this study showed that LVV, LVW and STh were significantly increased after AMI, indicating the occurrence of LVRM.This is also in agreement with the reports of Pfeffer 8 and Litwin. 9 Most importantly, the major finding of this study is that cilazapril and carvedilol, alone and in combination, can attenuate LV dilatation, since LVV was decreased by 12%, 14% and 15%, respectively. No similar results have been previously reported in the literature. LV dilatation after AMI, which is one of the key characters of LVRM, can promote further LV enlargement through increasing systolic and diastolic wall stress, and finally results in the development of CHF. 13 It is also the most powerful predictor of poor prognosis.Thus, the findings of attenuation of LV dilatation by cilazapril, carvedilol and their combination is not only of clinical significance, but also means that carvedilol is as effective as cilazapril in preventing post-infarction LVRM, and can be routinely used early after AMI.The mechanism of attenuating LV dilatation by carvedilol is probably multifactorial and includes the inhibition of SNS activation,including the reduction of LV pre-load and afterload associated with α 1 -blockade, reduction in myocardial oxygen consumption with β-blockade and antioxidant effects. 6, 14 PAPER Table 1 The effects of cilazapril, carvedilol and their combination on haemodynamic variables. The other major finding in this study is that cilazapril and carvedilol, alone and in combination, can all attenuate the hypertrophy of non-infarcted myocardium after AMI, with the combination therapy superior to monotherapy. The results also show that carvedilol is as effective as cilazapril in this respect, which is a previously unreported finding.Hypertrophy of non-infarcted myocardium is the main pathologic basis of LVRM and is initiated and promoted by haemodynamic abnormalities and SNS and RAS activation. During the early phase of AMI, this hypertrophy can improve LV contractility and reduce LV wall stress, which is beneficial for compensation of the reduced LV function. However, it also exerts detrimental effects in LV enlargement because of the increase in wall stress, which in turn may promote further LV dilatation and finally lead to progressive LV dysfunction and heart failure. In addition, hypertrophy itself can also result in myocardial dysfunction and finally heart failure through myocardial fibroblast proliferation, collagen synthesis and severe fibrosis. 15 Thus, attenuation of hypertrophy of non-infarcted myocardium is also very important in preventing LVRM and heart failure.The mechanism by which cilazapril attenuates hypertrophy is the result of reduced angiotensin II (Ang II) production and bradykinin degradation via the inhibition of the circulatory and cardiac RAS, which not only attenuates the reactive cardiac hypertrophy by reducing pre-load, afterload and wall stress, but also directly prevents myocyte hypertrophy, fibroblast proliferation and collagen synthesis. [15] [16] [17] The possible mecha-nisms of carvedilol's beneficial effects include: 18 1) haemodynamic effects by reducing LV oxygen consumption and wall stress; 2) neurohormonal effects by inhibiting the growthpromoting effects of norepinephrine on cardiomyocytes and attenuating the collagen deposition in the non-infarcted zone. The underlying mechanism of the better effects of combination therapy on the hypertrophy may be due to more complete blockade of the growth-promoting effects of both Ang II and norepinephrine.
The effects of cilazapril, carvedilol and their combination on LV function
The results of this study showed that ±dp/dt and +dp/dt/LVSP were significantly decreased after AMI, indicating impairment of LV function, while cilazapril and carvedilol, alone and in combination, all improved LV function,with the combination therapy superior to cilazapril alone. This is consistent with the results of a study by Kramer. 19 Carvedilol improves LV function,not only by blockade of adrenergic receptors with direct protective effects against catecholamines on myocytes, and improved regional wall motion, but also by its potent antioxidant and vasodilator effects, protecting cardiomyocytes from oxygen free radical injury, reducing LV pre-load and afterload, and thus further reducing cardiomyocyte oxygen consumption. 5, 14 Clinical implications The rat model of post-infarction LVRM used for this study appears clinically relevant.Therapies that alter the remodelling process were first demonstrated using this model 8 and then reproduced later in the clinical setting. 2 Traditionally, the beneficial effects of β-blockade used in AMI are derived mainly from limiting MI size due to reduction of myocardial oxygen consumption.The current findings of this study suggest that the third generation β-blocker, carvedilol, has equivalent effects to cilazapril, an ACE-I, in attenuating LV dilatation and remodelling, and should be as routinely used early after AMI as ACE-I. Furthermore, the combined use of carvedilol with an ACE-I in AMI is probably superior to either monotherapy and, more importantly, carvedilol is not only of benefit in the treatment of heart failure as evidenced in clinical trials, but also potentially in the prevention of heart failure due to LVRM after AMI. Further studies including clinical trials are indicated to verify these findings.
